The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose
Open accessAbstract
Administering naloxone hydrochloride (naloxone) during an opioid overdose reverses the overdose and can prevent death. Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device. In August 2006, the Boston Public Health Commission passed a public health regulation that authorized an opioid overdose prevention program that included intranasal naloxone education and distribution of the spray to potential bystanders. Participants were taught by trained nonmedical needle exchange staff. After 15 months, the program provided training and intranasal naloxone to 385 participants who reported 74 successful overdose reversals. Problems with intranasal naloxone were uncommon. Overdose prevention education with distribution of intranasal naloxone is a feasible public health intervention to address opioid overdose.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This route of administration has been validated for both OT (6, 71) and NAL (72–74) in previous human studies”
From Oxytocin under opioid antagonism leads to supralinear enhancement of social attention (2017) · cites this paper as [74]
Citations
Cites
Increasing deaths from opioid analgesics in the United States
Paulozzi, L. J., Budnitz, D. S., & Xi, Y. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1276 · Cited by 696
Seal, K. H. (2005) · Journal of Urban Health · doi:10.1093/jurban/jti053 · Cited by 244
Prescribing Naloxone to Actively Injecting Heroin Users: A Program to Reduce Heroin Overdose Deaths
Maxwell, S., Bigg, D., Stanczykiewicz, K., & Carlberg-Racich, S. (2006) · Journal of Addictive Diseases · doi:10.1300/j069v25n03_11 · Cited by 242
Green, T. C., Heimer, R. R., & Grau, L. E. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02182.x · Cited by 192
Kelly, A., Kerr, D. C., Koutsogiannis, Z., Dietze, P., Patrick, I., & Walker, T. (2005) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06550.x · Cited by 163
Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes
Dettmer, K., Saunders, B., & Strang, J. (2001) · BMJ · doi:10.1136/bmj.322.7291.895 · Cited by 158
Tobin, K. E., Sherman, S. G., Beilenson, P. L., Welsh, C., & Latkin, C. A. (2008) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2008.03.002 · Cited by 149
Take‐home naloxone to reduce heroin death
Baca, C. T., & Grant, K. J. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01259.x · Cited by 137
Barton, E. D., Colwell, C. B., Wolfe, T. R., Fosnocht, D., Gravitz, C. S., Bryan, T. S., Dunn, W., Benson, J., & Bailey, J. E. (2005) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2005.03.007 · Cited by 136
Galea, S., Worthington, N., Piper, T. M., Nandi, V., Curtis, M., & ROSENTHAL, D. M. (2005) · Addictive Behaviors · doi:10.1016/j.addbeh.2005.07.020 · Cited by 131
Flagged first, then by citations
Research works printed but not linked: 5
- Centers for Disease Control and Prevention, 2000, MMWR Morb Mortal Wkly Rep, 49, 636
- Centers for Disease Control and Prevention, 2000, MMWR Morb Mortal Wkly Rep, 49, 633
- Sherman SG, Int J Drug Policy
- Tobin KE, Int J Drug Policy
- Davis JE, 2008, J Emerg Med
Cited by
Sorted by citations
Items 101–200 of 250
Strang, J., McDonald, R., Tas, B., & Day, E. (2016) · Addiction · doi:10.1111/add.13209 · Cited by 38
Purssell, R. A., Godwin, J., Moe, J., Buxton, J. A., Crabtree, A., Kestler, A. M., DeWitt, C., Scheuermeyer, F. X., Erdelyi, S., Balshaw, R. F., et al. (2020) · Clinical Toxicology · doi:10.1080/15563650.2020.1758325 · Cited by 38
Expanding Access to Naloxone in the United States
Doyon, S., Aks, S. E., & Schaeffer, S. E. (2014) · Journal of Medical Toxicology · doi:10.1007/s13181-014-0432-1 · Cited by 37
Berland, N., Lugassy, D. M., Fox, A. D., Goldfeld, K. S., Oh, S.-Y., Tofighi, B., & Hanley, K. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1572048 · Cited by 37
Ashrafioun, L., Gamble, S., Herrmann, M., & Baciewicz, G. (2015) · Substance Abuse · doi:10.1080/08897077.2015.1110550 · Cited by 38
Lenton, S. R., Dietze, P., Olsen, A., Wiggins, N., McDonald, D., & Fowlie, C. (2014) · Drug and Alcohol Review · doi:10.1111/dar.12198 · Cited by 36
Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users
Acharya, M., Chopra, D., Hayes, C. J., Teeter, B. S., & Martin, B. C. (2020) · Value in Health · doi:10.1016/j.jval.2019.12.002 · Cited by 38
Zang, X., Macmadu, A., Krieger, M. S., Behrends, C. N., Green, T. C., Morgan, J. R., Murphy, S. M., Nolen, S., Walley, A. Y., Schackman, B. R., et al. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103435 · Cited by 38
Faul, M., Aikman, S. N., & Sasser, S. M. (2016) · Prehospital Emergency Care · doi:10.3109/10903127.2015.1088605 · Cited by 35
Hughto, J. M. W., Gordon, L. K., Stopka, T. J., Case, P., Palacios, W. R., Tapper, A. R., & Green, T. C. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1946893 · Cited by 37
Modeling of overdose and naloxone distribution in the setting of fentanyl compared to heroin
Coffin, P. O., Maya, S., & Kahn, J. G. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109478 · Cited by 35
Naloxone use among overdose prevention trainees in New York City: A longitudinal cohort study
Siegler, A., Huxley‐Reicher, Z., Maldjian, L., Jordan, R., Oliver, C., Jakubowski, A. U., & Kunins, H. V. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.06.029 · Cited by 34
Bowles, J. M., & Lankenau, S. E. (2018) · Qualitative Health Research · doi:10.1177/1049732318800289 · Cited by 34
Bascou, N. A., Haslund-Gourley, B. S., Amber-Monta, K., Samson, K. R., Goss, N. C., Meredith, D. M., Friedman, A. V., Needleman, A., Kumar, V. K., & Fischer, B. D. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00589-6 · Cited by 32
Opioid Harm Reduction Strategies: Focus on Expanded Access to Intranasal Naloxone
Wermeling, D. P. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.7.627 · Cited by 31
Macias‐Konstantopoulos, W., Heins, A., Sachs, C. J., Whiteman, P. J., Wingkun, N., & Riviello, R. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2020.11.008 · Cited by 35
Mayet, S., Manning, V., Williams, A., Loaring, J., & Strang, J. (2010) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2010.09.008 · Cited by 31
Critical opportunities for public health law: a call for action
Mello, M. M., Wood, J., Burris, S., Wagenaar, A. C., Ibrahim, J. K., & Swanson, J. W. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301281 · Cited by 30
Availability of naloxone in Canadian pharmacies:a population-based survey
Cressman, A. M., Mazereeuw, G., Guan, Q., Jia, W., Gomes, T., & Juurlink, D. N. (2017) · CMAJ Open · doi:10.9778/cmajo.20170123 · Cited by 30
Modeling dynamics of fatal opioid overdose by state and across time
Cooper, R. L., Thompson, J., Edgerton, R. D., Watson, J. A., MacMaster, S. A., Kalliny, M., Huffman, M., Juárez, P. D., Matthews-Juarez, P., Tabatabai, M., et al. (2020) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2020.101184 · Cited by 30
Klimas, J., Egan, M., Tobin, H. M., Coleman, N., & Bury, G. (2015) · BMC Medical Education · doi:10.1186/s12909-015-0487-y · Cited by 28
Hedrich, D., & Hartnoll, R. (2020) · Textbook of Addiction Treatment · doi:10.1007/978-3-030-36391-8_52 · Cited by 38
Opioid overdose and naloxone education in a substance use disorder treatment program
Lott, D. C., & Rhodes, J. M. (2016) · American Journal on Addictions · doi:10.1111/ajad.12364 · Cited by 28
Samuels, E. A., Wentz, A. E., McCormick, M., McDonald, J., Marshall, B. D. L., Friedman, C., Koziol, J. A., & Alexander-Scott, N. E. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.02.004 · Cited by 27
Papp, J., Vallabhaneni, M., Morales, A., & Schrock, J. W. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4734-5 · Cited by 27
Green, T. C., Zaller, N. D., Rich, J. D., Bowman, S., & Friedmann, P. D. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01136.x · Cited by 27
McCrea, A. M. (2019) · Administration & Society · doi:10.1177/0095399719878727 · Cited by 29
Dworkis, D. A., Weiner, S. G., Liao, V. T., Rabickow, D., & Goldberg, S. A. (2018) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2018.4.37054 · Cited by 26
Management of Opioid Analgesic Overdose
Throckmorton, D. C., Compton, W. M., & Lurie, P. G. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1209707 · Cited by 26
Calcaterra, S. L., Severtson, S. G., Bau, G. E., Margolin, Z. R., Bucher‐Bartelson, B., Green, J., & Dart, R. C. (2018) · Clinical Toxicology · doi:10.1080/15563650.2018.1457792 · Cited by 26
Gao, X., Kong, N., & Griffin, P. M. (2023) · Manufacturing & Service Operations Management · doi:10.1287/msom.2022.0166 · Cited by 24
Lim, J. K., Forman, L. S., Ruiz, S., Xuan, Z., Callis, B. P., Cranston, K., & Walley, A. Y. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.06.033 · Cited by 24
Distribution of naloxone for overdose prevention to chronic pain patients
Coe, M. A., & WALSH, S. L. (2015) · Preventive Medicine · doi:10.1016/j.ypmed.2015.05.016 · Cited by 24
Wenger, L. D., Doe-Simkins, M., Wheeler, E., Ongais, L., Morris, T., Bluthenthal, R. N., Kral, A. H., & Lambdin, B. H. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00639-z · Cited by 25
Development of a targeted naloxone coprescribing program in a primary care practice
Wilson, C. G., Rodriguez, F., Carrington, A. C., & Fagan, E. B. (2017) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2016.12.076 · Cited by 24
Kobayashi, L., Green, T. C., Bowman, S. E., Ray, M., McKenzie, M., & Rich, J. D. (2016) · Simulation in Healthcare The Journal of the Society for Simulation in Healthcare · doi:10.1097/sih.0000000000000182 · Cited by 22
Currin, J. M., Hubach, R. D., & Croff, J. M. (2019) · Journal of Homosexuality · doi:10.1080/00918369.2019.1616429 · Cited by 25
Green, T. C., Donovan, E., Klug, B., Case, P., Baird, J. B., Burstein, D., Tapper, A. R., Walley, A. Y., & Bratberg, J. P. (2020) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2020.03.005 · Cited by 21
Nolte, K., Romo, E., Stopka, T. J., Drew, A., Dowd, P., Toro-Mejías, L. M. D., Bianchet, E., & Friedmann, P. D. (2022) · The Journal of Rural Health · doi:10.1111/jrh.12660 · Cited by 21
Neira-León, M., Barrio, G., Bravo, M. J., Brugal, M. T., de la Fuente, L., Domingo‐Salvany, A., Pulido, J., & Santos, S. (2010) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2010.06.003 · Cited by 21
Marcu, G. M., Aizen, R., Roth, A. M., Lankenau, S. E., & Schwartz, D. G. (2019) · JAMIA Open · doi:10.1093/jamiaopen/ooz068 · Cited by 21
Law, C. T., Moenig, C., Jeilani, H., Jeilani, M., & Young, T. (2023) · BMJ Innovations · doi:10.1136/bmjinnov-2021-000861 · Cited by 20
Now is the time to take steps to allow peer access to naloxone for heroin overdose in Australia
Lenton, S. R., Dietze, P., Degenhardt, L. J., Darke, S. G., & Butler, T. G. (2009) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00125.x · Cited by 20
Bonar, E. E., & Bohnert, A. M. (2016) · Substance Use & Misuse · doi:10.3109/10826084.2016.1168447 · Cited by 20
Dunn, K. E., Barrett, F. S., & Bigelow, G. E. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.03.011 · Cited by 20
Jones, J. D., Campbell, A. N. C., Brandt, L., Metz, V. E., Martinez, S., Wall, M. M., Corbeil, T., Andrews, H., Castillo, F., Neale, J., et al. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109505 · Cited by 19
Non-Fatal Opioid Overdose and Major Depression among Street-Recruited Young Heroin Users
Chahua, M., Sordo, L., Barrio, G., Domingo‐Salvany, A., Brugal, M. T., Molist, G., de la Fuente, L., Bravo, M. J., & and ITINERE Project Group (2013) · European Addiction Research · doi:10.1159/000346787 · Cited by 20
Guo, H., Xie, Q., Cui, J., Xu, D., Deji, C., Chen, Y., Wang, Y., & Lai, J. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24427 · Cited by 18
Opioid Drug Overdoses: A Prescription for Harm and Potential for Prevention
Dasgupta, N., Sanford, C., Albert, S., & Brason, F. W. (2009) · American Journal of Lifestyle Medicine · doi:10.1177/1559827609348462 · Cited by 18
Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose
Yokell, S. M. A., Zaller, N. D., Green, T. C., McKenzie, M., & Rich, J. D. (2012) · Journal of Opioid Management · doi:10.5055/jom.2012.0098 · Cited by 18
Dadiomov, D., Bolshakova, M., Mikhaeilyan, M., & Trotzky‐Sirr, R. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00651-3 · Cited by 17
Wright, Q. E., Higginbotham, S. K., Bunk, E., & Covvey, J. R. (2020) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.11.027 · Cited by 18
Thylstrup, B., Hesse, M., Jørgensen, M., & Thiesen, H. (2019) · Harm Reduction Journal · doi:10.1186/s12954-019-0328-0 · Cited by 17
Freeman, P. R., Walley, A. Y., Winhusen, T. M., Oga, E. A., Villani, J., Hunt, T., Chandler, R. K., Oyler, D. R., Reilly, B., Gelberg, K. H., et al. (2024) · American Journal of Public Health · doi:10.2105/ajph.2024.307845 · Cited by 15
Feasibility of Bystander Administration of Public-Access Naloxone for Opioid Overdose
Goldberg, S. A., Dworkis, D. A., Liao, V. T., Eyre, A. J., Albert, J., Fawcett, M. M., Narovec, C. M., DiClemente, J., & Weiner, S. G. (2018) · Prehospital Emergency Care · doi:10.1080/10903127.2018.1461284 · Cited by 15
Hedrich, D., & Hartnoll, R. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_133 · Cited by 15
Antoniou, T., Martins, D., Campbell, T. J., Tadrous, M., Munro, C., Leece, P., Mamdani, M., Juurlink, D. N., & Gomes, T. (2020) · Addiction · doi:10.1111/add.15324 · Cited by 14
Goldman, J. A., Krieger, M. S., Buxton, J. A., Lysyshyn, M., Sherman, S. G., Green, T. C., Bernstein, E., Hadland, S. E., & Marshall, B. D. L. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1616245 · Cited by 14
Troberg, K., Isendahl, P., Blomé, M. A., Dahlman, D., & Håkansson, A. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-2470-3 · Cited by 14
Treating Opioid Use Disorder in General Medical Settings
(2021) · Springer eBooks · doi:10.1007/978-3-030-80818-1 · Cited by 13
Mokhtari, A. K., Mikdad, S., Luckhurst, C. M., Hwabejire, J. O., Fawley, J. A., Parks, J. J., Mendoza, A. E., Kaafarani, H. M. A., Velmahos, G. C., Bloemers, F. W., et al. (2022) · European Journal of Trauma and Emergency Surgery · doi:10.1007/s00068-022-01973-4 · Cited by 13
Wulz, J. L., Sung, H., Dugan, B. D., Wensel, T. M., Lander, R. D., & Manzella, B. A. (2017) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2016.12.078 · Cited by 13
Rich, J. D., Green, T. C., & McKenzie, M. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1014490 · Cited by 13
Doyon, S., Benton, C., Anderson, B. A., Baier, M., Haas, E. E., Hadley, L., Maehr, J., Rebbert‐Franklin, K., Olsen, Y. K., & Welsh, C. (2016) · American Journal on Addictions · doi:10.1111/ajad.12384 · Cited by 12
Beletsky, L. A., Burris, S. C., & Kral, A. H. (2009) · SSRN Electronic Journal · doi:10.2139/ssrn.1437163 · Cited by 12
Intranasal delivery of iron chelators and management of central nervous system disease
Cheng, R., & Kim, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1709259 · Cited by 13
Opioid Overdose Prevention in a Residential Care Setting: Naloxone Education and Distribution
Pade, P., Fehling, P., Collins, S., & Martín, L. (2016) · Substance Abuse · doi:10.1080/08897077.2016.1176978 · Cited by 11
Sarasa‐Renedo, A., Espelt, A., Folch, C., Vecino, C., Majó, X., Castellano, Y., Casabona, J., & Brugal, M. T. (2014) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2013.10.012 · Cited by 11
Olding, M., Boyd, J., Kerr, T. H., Fowler, A., & McNeil, R. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103929 · Cited by 11
A pilot study investigating cognitive impairment associated with opioid overdose
Mahoney, J. J., Winstanley, E. L., Castillo, F., Luba, R. R., Marton, J. L., Alschuler, D. M., Liu, Y., & Comer, S. D. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109865 · Cited by 11
Dahlem, C. H., Scalera, M., Chen, B., McCabe, S. E., & Boyd, C. J. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1671946 · Cited by 11
Lambdin, B. H., Bluthenthal, R. N., Garner, B. R., Wenger, L. D., Browne, E. N., Morris, T., Ongais, L., Megerian, C. E., & Kral, A. H. (2024) · Implementation Science · doi:10.1186/s13012-024-01354-y · Cited by 9
Wilder, C. M., Brason, F. W., Clark, A. K., Galanter, M. S., Walley, A. Y., & Winstanley, E. L. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000032 · Cited by 9
Who is Overdosing? An Updated Picture of Overdose Deaths From 2008 to 2015
Eigner, G., Henriksen, B. S., Huynh, P., Murphy, D., Brubaker, C., Sanders, J., & McMahan, D. A. (2017) · Health Services Research and Managerial Epidemiology · doi:10.1177/2333392817727424 · Cited by 9
Common toxidromes in movement disorder neurology
Malek, N., & Baker, M. R. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134254 · Cited by 10
Murphy, C. M. (2015) · Emergency medical services · doi:10.1002/9781118990810.ch46 · Cited by 9
Legal review of state emergency medical services policies and protocols for naloxone administration
Smart, R., Haffajee, R. L., & Davis, C. S. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109589 · Cited by 8
Cagle, J. G., McPherson, M. L., Frey, J. J., Sacco, P., Ware, O. D., Hoffmann, D. E., & Guralnik, J. M. (2021) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2021.02.023 · Cited by 8
Wiener, R. C., Waters, C., Bhandari, R., Shockey, A. K. T., & Panagakos, F. S. (2019) · Journal of Dental Education · doi:10.21815/jde.019.115 · Cited by 7
Harm Reduction Strategies for People Who Use Drugs
Shah, R. R., Shay, J., & Komaromy, M. S. (2024) · JAMA · doi:10.1001/jama.2024.23605 · Cited by 6
Locational and Contextual Attributes of Opioid Overdoses in New Jersey
Treitler, P. C., Powell, K. G., Morton, C. M., Peterson, N. A., Hallcom, D. K., & Borys, S. V. (2021) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2021.1901203 · Cited by 6
Pediatric Ingestions: Emergency Department Management.
Tarango, S. M., & Liu, D. R. (2016) · PubMed · Cited by 5
Dasgupta, N., Bell, A., Visnich, M., Doe-Simkins, M., Wheeler, E., Sibley, A. L., Nocera, M., Seitz, A. E., Chang, D., Barlow, S., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0315026 · Cited by 4
Current Opiate and Opioid Hazards in Children and Adolescents
Chhabra, N., & Aks, S. E. (2017) · Clinical Pediatric Emergency Medicine · doi:10.1016/j.cpem.2017.07.006 · Cited by 4
Stager, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00108-1 · Cited by 4
Intranasal overdose reversal formulations: a rapid review of available agents
Bernosky‐Smith, K. A., Painter, O. B., Butler, S., Patel, D., Clemency, B. M., & Lynch, J. J. (2025) · Pain Management · doi:10.1080/17581869.2025.2461445 · Cited by 3
Rangachari, P., & Tran, A. H. (2025) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s521720 · Cited by 3
“Take home” naloxone: what does the evidence base tell us?
Breedvelt, J., Tracy, D. K., Dickenson, E. C., & Dean, L. V. (2015) · Drugs and Alcohol Today · doi:10.1108/dat-03-2015-0017 · Cited by 3
Webster, L., Eisenberg, A. L., Bohnert, A. M., Kleinberg, F., & Ilgen, M. A. (2012) · Archives of Suicide Research · doi:10.1080/13811118.2012.695273 · Cited by 3
“I feel safe here”: Participants identify key components of syringe access programs
Ostrander, N., & Carlberg-Racich, S. (2021) · Journal of Prevention & Intervention in the Community · doi:10.1080/10852352.2021.1915733 · Cited by 3
Argenyi, M. S., Evans, J. K., Gay, Y., Epstein, D. H., & Weiss, S. T. (2023) · Clinical Toxicology · doi:10.1080/15563650.2023.2229508 · Cited by 3
Metrebian, N., Carter, B., Eide, D., McDonald, R., Neale, J., Parkin, S., Dascal, T., Mackie, C. J., Day, E., Guterstam, J., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-16445-6 · Cited by 3
Brandt, L., Yanagida, T., Campbell, A. N. C., Jones, J. D., Schultes, M.-T., Martinez, S., & Comer, S. D. (2021) · Global Implementation Research and Applications · doi:10.1007/s43477-021-00021-4 · Cited by 3
Nalokson nesespray kan redusere risikoen for dødelige heroinoverdoser
Lobmaier, P. P. K., Dalsbø, T. K., & Clausen, T. (2011) · Norsk Epidemiologi · doi:10.5324/nje.v21i1.1433 · Cited by 2
Herrera, A. N. S., & Rios, K. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01250-8 · Cited by 2
A Review of YouTube Videos About the Opioid Antagonist Medication Naloxone
Kernan, W. D., Basch, C. H., Segall, L., & Garcia, P. (2020) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2020.1752079 · Cited by 2
Characteristics of Individuals Witnessing Drug Overdoses in Canada
Kleinman, R. A. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08268-3 · Cited by 2
Nesen – mer enn til å snyte seg i!
Dale, O. (2010) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.10.0378 · Cited by 2
Dasgupta, N., Bell, A., Visnich, M., Doe-Simkins, M., Wheeler, E., Sibley, A. L., Nocera, M., Seitz, A. E., Chang, D., Barlow, S., et al. (2024) · medRxiv · doi:10.1101/2024.11.21.24317731 · Cited by 2
Krey, M., Villa, S., Gharibyar, N., & Mesdaq, H. (2024) · Pharmacology & Pharmacy · doi:10.4236/pp.2024.152003 · Cited by 1
Metadata
- Authors
- Doe-Simkins, M., Walley, A. Y., Epstein, A., & Moyer, P.
- Affiliations
- Boston University (US)
- Venue
- American Journal of Public Health
- Publisher
- American Public Health Association
- Published
- 2009-05
- Volume
- 99
- Issue
- 5
- Pages
- 788-791
- ISSN
- 0090-0036 (ISSN-L)
- 1541-0048
- PMC
- PMC2667836
- OpenAlex
- W2160243203
- Cited by
- 250
- References
- 25
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 9 · 2023: 9 · 2022: 19 · 2021: 20 · 2020: 13 · 2019: 17 · 2018: 20 · 2017: 19 · 2016: 25 · 2015: 22 · 2014: 22 · 2013: 14 · 2012: 9
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Public Health (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Keywords
- intranasal naloxone, opioid overdose, overdose reversal, bystander intervention, public health regulation, harm reduction, opioid use disorder
- MeSH terms
- Administration, Intranasal, Adult, Emergency Medical Services, Female, Humans, Male, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Risk Factors, Program Evaluation, Needle-Exchange Programs, Drug Overdose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review